Excelra Recognized as a Leader in Everest Group’s Pharmaceutical R&D IT Services PEAK Matrix 2026
Excelra, a global life‑sciences data and informatics company, announced on 4 November 2026 from Hyderabad, India, that it has been positioned as a Leader in the Everest Group’s Pharmaceutical R&D IT Services PEAK Matrix® Assessment 2026. The assessment evaluated 34 service providers and identified nine Leaders, with Excelra ranking among them based on market impact, vision and capability, and a comprehensive RFI process that incorporated client references.
The Everest Group’s evaluation credited Excelra’s combination of curated scientific data, advanced scientific AI, and deep domain expertise. Central to this recognition is Excelra’s flagship product GOSTAR®, which contains 37 million bioactivity data points and is described as AI/ML‑ready. The company’s scientific AI solutions are built on high‑quality scientific data and are purpose‑designed for life‑sciences research and development.
Excelra also highlighted recent mergers and acquisitions that have expanded its on‑shore scientific consulting talent, thereby improving proximity to global pharmaceutical clients. Its partner ecosystem now spans leading cloud providers, laboratory informatics platforms, and other technology platforms, further reinforcing its service capabilities.
Durga Ambati, Vice President at Everest Group, stated that pharmaceutical enterprises are seeking partners that blend deep scientific and functional expertise with robust data, AI, and platform capabilities, and that Excelra stands out because of its proprietary scientific datasets, including GOSTAR®, which supports structure‑activity relationship intelligence for AI‑driven drug discovery, as well as verticalized scientific AI solutions covering multimodal data analytics, scientific knowledge retrieval, and regulatory intelligence.
Anandbir Brar, Chief Executive Officer of Excelra, affirmed the company’s “science‑first” conviction, noting that the recognition validates the importance of scientific depth alongside scale in pharma R&D, especially as AI becomes central to research processes.
The full Everest Group assessment can be accessed at https://www.excelra.com/publications/everest-group-peak-matrix-2026/#download-the-report.
About Excelra
Excelra engineers AI‑driven R&D solutions by combining AI‑ready data and platforms, connected lab informatics, and multi‑omics expertise to transform R&D complexity into defensible decisions.
About Everest Group
Everest Group is a leading research firm that assists business leaders in making confident decisions by applying contextualized problem‑solving to market challenges.
Disclaimer: This press release is distributed under an arrangement with PRNewswire; PTI assumes no editorial responsibility.